Re-Evaluation of Efficacy of Moderate-Intensity Statins in Korean Patients with Type 2 Diabetes Mellitus.
作者信息
Kim Soo Kyoung
机构信息
Department of Internal Medicine and Institute of Health Sciences, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.
出版信息
Diabetes Metab J. 2017 Feb;41(1):20-22. doi: 10.4093/dmj.2017.41.1.20.
Abstract
摘要
相似文献
1
Re-Evaluation of Efficacy of Moderate-Intensity Statins in Korean Patients with Type 2 Diabetes Mellitus.
Diabetes Metab J. 2017 Feb;41(1):20-22. doi: 10.4093/dmj.2017.41.1.20.
2
Letter: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30).
Diabetes Metab J. 2017 Apr;41(2):150-151. doi: 10.4093/dmj.2017.41.2.150.
3
Response: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30).
Diabetes Metab J. 2017 Apr;41(2):152-153. doi: 10.4093/dmj.2017.41.2.152.
4
Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins.
Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):315-22. doi: 10.1161/CIRCOUTCOMES.111.000015. Epub 2013 May 14.
5
Putting the diabetes risk due to statins in perspective: a re-evaluation using the complementary outcome.
Nutr Metab Cardiovasc Dis. 2014 Jul;24(7):705-8. doi: 10.1016/j.numecd.2014.02.012. Epub 2014 Mar 1.
6
Effects of high intensity interval training versus moderate intensity continuous training on the reduction of oxidative stress in type 2 diabetic adult patients: CAT.
Medwave. 2015 Aug 13;15(7):e6212. doi: 10.5867/medwave.2015.07.6212.
7
Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
Curr Med Res Opin. 2007 Sep;23(9):2125-33. doi: 10.1185/030079907X219580.
8
REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.
J Clin Endocrinol Metab. 2006 Feb;91(2):383-92. doi: 10.1210/jc.2005-2084. Epub 2005 Nov 15.
9
Statins and diabetes risk: how real is it and what are the mechanisms?
Curr Opin Lipidol. 2015 Jun;26(3):228-35. doi: 10.1097/MOL.0000000000000172.
10
Efficacy and safety of statins in the treatment of diabetic dyslipidemia.
Tunis Med. 2010 Feb;88(2):80-4.
引用本文的文献
1
Low-density lipoprotein cholesterol goal attainment rates in high-risk patients with cardiovascular diseases and diabetes mellitus in Korea: a retrospective cohort study.
Lipids Health Dis. 2020 Jan 11;19(1):5. doi: 10.1186/s12944-019-1158-5.
2
Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study.
Korean J Intern Med. 2019 Nov;34(6):1252-1262. doi: 10.3904/kjim.2018.133. Epub 2018 Sep 1.
本文引用的文献
1
Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus.
Diabetes Metab J. 2017 Feb;41(1):23-30. doi: 10.4093/dmj.2017.41.1.23. Epub 2016 Dec 16.
2
Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.
Eur J Clin Pharmacol. 2015 Mar;71(3):329-40. doi: 10.1007/s00228-014-1800-0. Epub 2015 Jan 30.
3
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12.
4
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
5
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.
Lancet. 2006 Sep 30;368(9542):1155-63. doi: 10.1016/S0140-6736(06)69472-5.
6
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.
Clin Pharmacol Ther. 2005 Oct;78(4):330-41. doi: 10.1016/j.clpt.2005.06.013.
7
Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.
J Clin Pharmacol. 2004 Oct;44(10):1083-105. doi: 10.1177/0091270004268128.
8
Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia.
J Atheroscler Thromb. 2003;10(6):329-36. doi: 10.5551/jat.10.329.
9
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
BMC Fam Pract. 2003 Dec 1;4:18. doi: 10.1186/1471-2296-4-18.
10
Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients.
Circ J. 2003 Apr;67(4):287-94. doi: 10.1253/circj.67.287.
Zotero 插件